Ibrutinib-related skin cancer: A pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System

Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has revolutionised the treatment for multiple lymphoproliferative disorders and chronic graft versus host disease [1]. It is explored in the treatment of more and more cancer types and presents anti-skin cancer activity as inhibiting the proliferation of skin cancer cells and inducing apoptosis and autophagy in basic research [2]. However, in a phase II single-arm clinical trial which further assessed the ibrutinib effect on melanoma cells, no antitumour responses were seen [3].
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research